Here are five things to note:
1. The device is intended to deliver cells to a damaged site in need of facilitated repair.
2. BioRestorative Therapies plans to further the design to allow for substance delivery to certain locations in the body while reducing damage to surrounding structures.
3. The curved needle works with pre-curved nested cannulae, allowing therapeutics to be placed in areas where direct access is impossible.
4. BioRestorative Therapies’ licensor, Regenerative Sciences, received the patent in August 2015.
5. BioRestorative Therapies has an exclusive, royalty-bearing license from Regenerative to use the device for administering cells to the spine.
More articles on devices:
Alphatec company shares increase by 9.4% — 6 points
Ellipse Technologies prepares IPO filing: 6 things to know
ConforMIS reports Q3 revenue up 20%, net loss of $17.1M after voluntary recall: 8 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
